Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its blockbuster drug Keytruda (pembrolizumab) as an adjuvant treatment in newly diagnosed, high-risk endometrial cancer failed to meet the primary endpoint of disease-free survival (DFS). Although the analysis of the co-primary endpoint of overall survival (OS) was discontinued, MSD is continuing to evaluate the data from the study.
The company highlighted that no new safety signals were identified in the trial.
As stated in the press release, Keytruda has existing approvals for advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as well as advanced endometrial carcinoma that is mismatch repair deficient (dMMR) or MSI-H.- Flcube.com
